Posted by Michael Wonder on 19 Aug 2023
Veopoz (pozelimab-bbfg) receives FDA approval as the first treatment for children and adults with CHAPLE disease
18 August 2023 - Approval represents tenth FDA approved medicine invented by Regeneron.
Regeneron Pharmaceuticals today announced the US FDA has approved Veopoz (pozelimab-bbfg) for the treatment of adult and paediatric patients 1 year of age and older with CHAPLE disease, also known as CD55 deficient protein-losing enteropathy.
